10x Genomics, Inc. (NASDAQ:TXG) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET
Company Participants
Cassie Corneau - Senior Director, Head of Investor Relations and Strategic Finance
Serge Saxonov - Chief Executive Officer and Co-Founder
Adam Taich - Chief Financial Officer
Conference Call Participants
Tejas Savant - Morgan Stanley
Tycho Peterson - Jefferies
Doug Schenkel - Wolfe Research
Dan Arias - Stifel Nicolaus
Dan Brennan - TD Cowen
Mason Carrico - Stephens
Puneet Souda - Leerink Partners
Rachel Vatnsdal - J.P. Morgan
Kyle Mikson - Canaccord Genuity
Patrick Donnelly - Citi
Michael Ryskin - Bank of America
Subbu Nambi - Guggenheim Securities
Matt Larew - William Blair
Matt Sykes - Goldman Sachs
Operator
Thank you for standing by. My name is Mark, and I will be your conference operator today. At this time, I'd like to welcome everyone to the 10x Genomics' Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]
I would now like to turn the call over to Cassie Corneau, Senior Director, Head of Investor Relations and Strategic Finance. Cassie, please go ahead.
Cassie Corneau
Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the third quarter ended September 30, 2024. If you have not received this news release, or if you would like to be added to the company's distribution list, please send an email to investors@10xgenomics.com. An archived webcast of this call will be available on the investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.